Voloridge Investment Management LLC Sells 85,242 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Voloridge Investment Management LLC decreased its holdings in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 33.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 171,537 shares of the company's stock after selling 85,242 shares during the quarter. Voloridge Investment Management LLC owned approximately 0.36% of Mirum Pharmaceuticals worth $7,093,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Jones Financial Companies Lllp increased its position in Mirum Pharmaceuticals by 100.0% during the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock worth $30,000 after acquiring an additional 357 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Mirum Pharmaceuticals in the 4th quarter worth approximately $35,000. R Squared Ltd bought a new stake in shares of Mirum Pharmaceuticals in the 4th quarter valued at $69,000. AlphaQuest LLC increased its stake in shares of Mirum Pharmaceuticals by 969.6% in the 4th quarter. AlphaQuest LLC now owns 1,829 shares of the company's stock valued at $76,000 after acquiring an additional 1,658 shares in the last quarter. Finally, Summit Investment Advisors Inc. increased its stake in shares of Mirum Pharmaceuticals by 8.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,155 shares of the company's stock valued at $172,000 after acquiring an additional 312 shares in the last quarter.

Mirum Pharmaceuticals Trading Up 0.2%

NASDAQ MIRM traded up $0.09 on Friday, reaching $44.09. 52,943 shares of the company were exchanged, compared to its average volume of 518,587. The business's fifty day moving average price is $42.68 and its 200 day moving average price is $44.66. The stock has a market capitalization of $2.18 billion, a P/E ratio of -21.83 and a beta of 0.95. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $23.83 and a fifty-two week high of $54.23.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.05. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The firm had revenue of $111.59 million for the quarter, compared to the consensus estimate of $98.47 million. During the same quarter last year, the business posted ($0.54) EPS. The firm's quarterly revenue was up 61.2% compared to the same quarter last year. Analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Analysts Set New Price Targets

MIRM has been the topic of a number of research analyst reports. JMP Securities boosted their price target on shares of Mirum Pharmaceuticals from $74.00 to $76.00 and gave the stock a "market outperform" rating in a report on Friday, May 9th. Raymond James reissued a "strong-buy" rating on shares of Mirum Pharmaceuticals in a research note on Tuesday, May 13th. Robert W. Baird raised their price objective on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a research report on Thursday, February 27th. Finally, HC Wainwright restated a "buy" rating and set a $73.00 price target on shares of Mirum Pharmaceuticals in a report on Monday, May 19th. Ten equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $60.73.

Insider Activity

In other Mirum Pharmaceuticals news, Director Patrick J. Heron acquired 1,335 shares of the firm's stock in a transaction that occurred on Tuesday, March 4th. The stock was acquired at an average cost of $45.57 per share, with a total value of $60,835.95. Following the acquisition, the director now directly owns 163,643 shares of the company's stock, valued at $7,457,211.51. This represents a 0.82% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Christopher Peetz sold 27,279 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $44.21, for a total value of $1,206,004.59. Following the sale, the chief executive officer now owns 138,641 shares of the company's stock, valued at $6,129,318.61. This trade represents a 16.44% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 92,764 shares of company stock worth $4,109,161 over the last three months. 14.36% of the stock is currently owned by corporate insiders.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.